Cell line · CVCL_0041
Rh30
Cancer cell line, Homo sapiens. Alveolar rhabdomyosarcoma. 75 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Rh30. Cell lines, record CVCL_0041. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0041
On this page
Cell line
As Cellosaurus gives it.
- Name
- Rh30
- Accession
- CVCL_0041
- RRID
- RRID:CVCL_0041
- Synonyms
- RH30, RH-30, Rh-30, RH30SJ, SJRH-30, SJRH30, SJ-RH30, SJ-Rh 30, SJRH 30, SJCRH30, RC13, RMS-13, RMS 13, RMS13
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 17Y
- Category
- Cancer cell line
- Diseases
- Alveolar rhabdomyosarcoma (NCIt C3749); Alveolar rhabdomyosarcoma (ORDO Orphanet_99756)
- Derived from
- Bone marrow (metastatic)
- Secondary accessions
- CVCL_1696, CVCL_UF98
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers75
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Circulating free and low-density lipoprotein-bound GD2 can compete in vitro with neuroblastoma cells for binding therapeutic anti-GD2 antibodies. | J Circ Biomark | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-Risk Rhabdomyosarcomas Feature a Convergent Cell State. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma. | JCI Insight | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 75
See all 75 papersRelatives2
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | Rh30rVCR10 | CVCL_RR39 | Cell lines | |
| Derived from it | SJCRH30 POLG Y955C | CVCL_C1D0 | Cell lines |
Cell banks4
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0041
GET https://conductscience.org/api/cell-lines/v1/CVCL_0041/papers?page=2